乳腺癌质子治疗的临床实践：从筛选到治疗的单一中心经验

摘要(中文译文)

乳腺质子治疗能有效限制心脏、肺及对侧乳腺的照射剂量，与经典光子技术相比，这可能在临床上转化为更好的晚期耐受性。尽管乳腺质子治疗已在美国和部分欧洲国家开展，但目前法国在乳腺癌质子治疗方面的临床经验仍然有限。本研究旨在评估居里研究所乳腺癌质子治疗的临床实践，以便在更大范围内推广该技术。研究检索了所有因辅助乳腺质子治疗而被转诊至奥赛质子治疗中心（CPO，居里研究所）的乳腺癌患者的资料。我们分析了这些患者最终是否接受质子治疗的原因。2019年11月至2020年11月期间，共有11例乳腺癌患者在CPO接受了辅助质子治疗评估。其中2例最终接受了质子束治疗；辅助乳腺质子治疗耐受性良好。其余9例患者未接受质子治疗，原因是在患者评估时，质子治疗治疗室无法在可接受的时间期限内提供使用。尽管质子治疗具有剂量学优势且临床耐受性极佳，但质子治疗设备的可用性不足目前限制了乳腺质子治疗的更广泛开展。

Abstract

Breast protontherapy efficiently limits cardiac, lung and contralateral breast exposure, which may clinically translate into better late tolerance profile compared with classic photon techniques. While breast protontherapy is already implemented in the United States and in some European countries, clinical experience of breast cancer protontherapy is currently limited in France. The aim of this study is to evaluate the clinical practice of breast cancer protontherapy at the Institut Curie in order to implement this technique at a larger scale. Data from all breast cancer patients that have been addressed to the protontherapy centre of Orsay (CPO, Institut Curie) for adjuvant breast protontherapy were retrieved. We analysed why these patients were ultimately treated with protontherapy or not. Between November 2019 and November 2020, eleven breast cancer patients have been evaluated for adjuvant protontherapy at the CPO. Two of them were ultimately treated with proton beams; adjuvant breast protontherapy therapy was well tolerated. The nine other patients were not treated with protontherapy due to lack of availability of protontherapy treatment rooms in acceptable time limits, at the time of patient evaluation. Despite dosimetric advantages and excellent clinical tolerance, lack of availability of protontherapy machines currently limits wider implementation of breast protontherapy.

如何引用